Recognition of phenotypic variability in pediatric asthma allows for a more personalized
therapeutic approach. Knowledge of the underlying pathophysiological and molecular …

Background: Asthma has an important impact in terms of both direct and indirect costs. In
Europe, the disease costs€ 19 000 million a year. Moreover, the cost is greater among …

Background The new WHO air quality guidelines indicate that the air pollution disease
burden is greater than previously reported. We aimed to estimate the air pollution disease …

Asthma is considered the most prevalent chronic childhood disease worldwide. Physical
activity (PA) represents a tool to improve patients with respiratory diseases' health-related …

Background Childhood asthma is very prevalent and costs can be high, especially in severe
disease. This study aimed to estimate the cost of asthma in Portuguese children and the …

Asthma is one of the main chronic diseases in childhood, due to its high prevalence and its
social and health costs. This document is a summary of a consensus guideline approved by …

Background This study aimed at estimating the efficiency of palivizumab in the prevention of
Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32 day 1-35 …

Background Severe pediatric allergic asthma (SPAA) induces a huge economic burden in
terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of …

Objective The economic burden of severe asthma (SA) in children is poorly described. We
aimed to determine the healthcare costs of SA in children for the French national health …

El asma es una de las principales enfermedades crónicas de la infancia, por su elevada
prevalencia y por su coste sociosanitario. Este artículo es un resumen de la guía de …